- Home
- MODV vs IMUX Comparison
MODV vs IMUX Comparison
Compare MODV & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODV
- IMUX
- Stock Information
- Founded
- MODV 1996
- IMUX 2016
- Country
- MODV United States
- IMUX United States
- Employees
- MODV N/A
- IMUX N/A
- Industry
- MODV Transportation Services
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- MODV Consumer Discretionary
- IMUX Health Care
- Exchange
- MODV Nasdaq
- IMUX Nasdaq
- Market Cap
- MODV 81.8M
- IMUX 90.3M
- IPO Year
- MODV N/A
- IMUX N/A
- Fundamental
- Price
- MODV $0.99
- IMUX $0.98
- Analyst Decision
- MODV Buy
- IMUX Strong Buy
- Analyst Count
- MODV 4
- IMUX 6
- Target Price
- MODV $8.38
- IMUX $13.20
- AVG Volume (30 Days)
- MODV 433.4K
- IMUX 661.4K
- Earning Date
- MODV 05-01-2025
- IMUX 05-07-2025
- Dividend Yield
- MODV N/A
- IMUX N/A
- EPS Growth
- MODV N/A
- IMUX N/A
- EPS
- MODV N/A
- IMUX N/A
- Revenue
- MODV $2,787,586,000.00
- IMUX N/A
- Revenue This Year
- MODV N/A
- IMUX N/A
- Revenue Next Year
- MODV $5.65
- IMUX N/A
- P/E Ratio
- MODV N/A
- IMUX N/A
- Revenue Growth
- MODV 1.32
- IMUX N/A
- 52 Week Low
- MODV $0.98
- IMUX $0.83
- 52 Week High
- MODV $32.82
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- MODV 28.87
- IMUX 45.24
- Support Level
- MODV $1.10
- IMUX $0.86
- Resistance Level
- MODV $1.34
- IMUX $1.01
- Average True Range (ATR)
- MODV 0.20
- IMUX 0.09
- MACD
- MODV 0.10
- IMUX -0.01
- Stochastic Oscillator
- MODV 5.17
- IMUX 42.53
About MODV ModivCare Inc.
ModivCare Inc is a technology-enabled healthcare services company that provides a suite of integrated supportive care solutions for payors and their members. The company is also a provider of non-emergency medical transportation, or NEMT, personal care, and remote patient monitoring, or RPM, solutions, which serve similar, highly vulnerable patient populations. Its operating segment includes NEMT, Personal Care, and Remote Patient Monitoring. The company generates maximum revenue from the NEMT segment.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.